World-Renowned Athlete Charles Leclerc Teams Up with Eight Sleep to Redefine Recovery
30.1.2025 19:00:00 EET | Business Wire | Press release
Charles Leclerc, the world-class racing driver known for his exceptional talent throughout his career, is teaming up with Eight Sleep, the world’s leading sleep fitness company, as an Athlete Ambassador and Investor. With this partnership, Leclerc joins the elite group of hundreds of professional athletes and successful entrepreneurs who use Eight Sleep’s world class sleep technology to fuel their performance, proving recovery is just as critical as speed on the track.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130814809/en/
World-Renowned Athlete Charles Leclerc Teams Up with Eight Sleep to Redefine Recovery (Photo: Business Wire)
As an elite athlete, Leclerc is accustomed to taking on extreme pressure with his sport, on top of navigating a grueling year-round travel schedule. As he gears up for the 2025 season, he knows that every detail matters to maintain peak physical and mental fitness, especially sleep.
Leclerc joins an elite roster of more than 300 professional athletes across various sports disciplines who rely on Eight Sleep to enhance their performance and recovery, including Taylor Fritz (who is also an investor in Eight Sleep), Brock Purdy, Aaron Judge, Jimmy Butler, and more. The partnership underscores Eight Sleep’s commitment to helping the world’s top performers unlock their full potential through advanced sleep fitness technology.
“Partnering with Eight Sleep was a natural choice for me because they share my commitment to pursue excellence,” said Charles Leclerc. “Sleeping on the Pod gives me so much feedback that is vital for my training - it tells me and my trainers how hard I should push myself, which is especially critical during the season when I can't afford to put too much pressure on the body given how demanding the races are. With these personalized insights, Eight Sleep has truly redefined how I approach sleep, giving me the edge to focus on the job and deliver on the track."
As an ambassador and investor, Leclerc is helping to set a new standard for future athletes, emphasizing the role of optimized sleep in maximizing performance and recovery. Leclerc will be equipped with the Pod throughout the 2025 season as he sets his sights on a world championship. With the Pod, Leclerc is equipped to recover faster and perform at his peak despite the relentless demands of his sport
“Growing up in Italy, motorsport was a huge part of my life, whether it was racing myself, helping my dad fix his racing car in the garage, or watching races at home,” said Matteo Franceschetti, Co-Founder and CEO at Eight Sleep. “I’ve watched Charles’ trajectory since his early days and I understand the hard work and discipline he has put in to stay mentally and physically strong as a top athlete. Our partnership with Charles proves that the Pod’s world-class technology sets the standard for anyone looking to optimize their health and performance.”
WHAT’S NEW AT EIGHT SLEEP
In 2024, Eight Sleep introduced major innovations and partnerships to redefine sleep fitness, including:
- Pod 4 Ultra: Eight Sleep’s most powerful sleep solution yet, clinically validated to increase sleep time by up to one hour per night.
- Sleep Elixir: A revolutionary sleep supplement developed with longevity expert Dr. Peter Attia. Powered by insights from over 600 million hours of sleep data, Sleep Elixir is the first supplement to evolve iteratively like software, creating a seamless, calm day-to-night transition.
- Athlete Partnerships: Eight Sleep continued to expand its roster of professional athlete ambassadors by signing the top US tennis player, Taylor Fritz, as an athlete ambassador and investor. Working with Fritz has helped to educate the new generation of rising tennis stars on the importance of quality sleep while taking on grueling travel schedules and week-long tournaments.
With nearly 1 billion hours of sleep data fueling its research and product development, Eight Sleep continues to redefine what’s possible for the world’s top performers. For more information, visit eightsleep.com. To access visuals, please visit the Digital Press Kit.
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Founded in 2014 and headquartered in New York City, their hardware, software, and AI technologies power the world’s top athletes, entrepreneurs, and everyday high performers, including Charles Leclerc, Taylor Fritz, Brock Purdy, Lucy Charles-Barclay, Aaron Judge, Jimmy Butler, and more. Eight Sleep was named one of Fast Company's Most Innovative Companies in 2019, 2022 and 2023. The company was also recognized two years in a row by TIME's “Best Inventions of the Year.” Eight Sleep is available for purchase in Australia, Canada, the European Union, United Kingdom, United Arab Emirates and United States via eightsleep.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130814809/en/
Contacts
MEDIA CONTACT
Taylor Georgeson
Jack Taylor PR
EightSleep@jacktaylorpr.com - eightsleep@jacktaylorpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom